The company, specialising in haematology and clinical chemistry analysers and reagents for medical and veterinary use, is fortifying its position in the rapidly growing Asia-Pacific (APAC) diagnostics market.
Hungary-based diagnostics solutions provider Diatron has officially entered the Indian market with the inauguration of a new office in New Delhi.
The company, specialising in haematology and clinical chemistry analysers and reagents for medical and veterinary use, aims to fortify its position in the rapidly growing Asia-Pacific (APAC) diagnostics market.
Commenting on the same, Peter Zsoka, CFO and board of directors at Diatron, Budapest, Hungary, said, "Our journey began five years ago with a vision to expand our regional presence. The inauguration of our new office in Delhi is a significant milestone, reflecting our dedication to the Indian market. We aim to commence reagent manufacturing in India by 2024, demonstrating our commitment to this region and the healthcare sector."
As per the company, establishing a sales presence in India is expected to bring several advantages to customers and partners. It ensures swift and timely support, expediting project progress for more efficient outcomes. The move also eliminates language barriers, fostering improved communication and collaboration.
With over three decades of experience, Diatron has focused on developing, manufacturing, and distributing high-quality diagnostic equipment tailored to the healthcare sector.
The company’s product range includes clinical chemistry and haematology analysers for human and veterinary use, contributing to early disease detection and timely treatments.
Diatron's global recognition is evident, with products actively used in more than 110 countries, showcasing the company's continuous growth driven by strong customer relationships.
The expansion into India follows the recent launch of Aquarius 3, Diatron's latest IVD hematology analyzer for Complete Blood Count testing.
Evolving from the Abacus 380, Diatron’s flagship analyser, the Aquarius 3 incorporates similar robust counting technology but is equipped with new features to enhance operability and connectivity.
India's clinical diagnostic market, valued at $1.25 billion in 2022, is estimated to expand at a CAGR of 9% from 2022-2030, reaching $2.5 billion in 2030.
In recent developments, Sterling Accuris Diagnostics and VPL Diagnostic have formed an alliance to enhance diagnostics and expand healthcare services. With this alliance, Sterling Accuris Diagnostics will be able to enhance and expand its diagnostics, medical, and healthcare service offerings and expand its customer base.
Also, in October, CORE Diagnostics partnered with CanCertain Healthcare, aiming to bring advancements to the realm of cancer treatment. This strategic collaboration centres on equipping healthcare providers and oncologists with a potent tool for making personalised treatment decisions, ultimately streamlining the patient's journey toward recovery.
Noteworthy players in this dynamic landscape include key entities like Dr Lal Pathlabs, RAINBOW Children's Medicare, and Metropolis Healthcare, contributing significantly to the sector's development and shaping the healthcare landscape in India.